Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
02.04. | Leqembi's EU review drags on; Sanofi gets a new development head | ||
02.04. | 'A cruel April Fool's joke': HHS layoffs characterized by confusion, errors | ||
02.04. | FDA device office hit in HHS layoffs | ||
02.04. | Newly launched genetic medicine CDMO acquires Landmark Bio | ||
01.04. | HHS begins layoffs in chaotic fashion | ||
01.04. | Judge overturns FDA's lab developed test regulation, siding with industry | ||
01.04. | RNA editing biotech Airna adds $155M in funding | ||
31.03. | Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks | ||
31.03. | Isomorphic raises $600M on big ambitions for AI drugmaking tech | ||
31.03. | FDA official's ouster sends shares of vaccine makers sliding | ||
31.03. | Lilly study data reinforce potential of new kind of heart drug | ||
31.03. | How discoverable, comparable and explorable is your data? | ||
28.03. | FDA approves first-of-its-kind RNA drug for hemophilia | ||
28.03. | Bluebird gets rival takeout offer from Ayrmid | ||
28.03. | FDA broadens use of Novartis' radiopharma drug Pluvicto | ||
28.03. | 'Everything is word of mouth': HHS employees face uncertainty in looming Trump layoffs | ||
28.03. | Lilly hits same Alzheimer's roadblock in Europe as Eisai, Biogen | ||
28.03. | Novo gains Lexicon obesity drug; CRISPR COO to step down | ||
27.03. | Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy | ||
27.03. | Alcon buys majority stake in IPO-seeking cell therapy startup Aurion | ||
27.03. | HHS to cut 10,000 staff in major restructuring under RFK Jr. | ||
26.03. | First Prader-Willi drug to reduce hunger approved by FDA | ||
26.03. | FDA approves first-of-its-kind antibiotic from GSK | ||
26.03. | Makary confirmed by Senate as FDA commissioner | ||
26.03. | Bayer gains cancer drug from China's Puhe; Axsome gets mixed ADHD data |